Financial News

Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal

Bausch + Lomb's stock leapt Friday, after the eye-health products company announced a $2.5 billion deal to buy Novartis' "dry eye" treatment Xiidra.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback